ClinicalTrials.gg
Status unknownNCT05374655Updated Apr 20, 2023

Outcomes Study of Glycosylated Hemoglobin Control in Cox-Maze IV During Cardiac Surgery

An interventional study of Preoperative blood glucose control in Cardiac Surgery, sponsored by Kun Hua. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by Kun Hua · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
180th of 256
148 · median 235
Started
2022
with 39 others
No phase
200 of 377
100 open now
Registered
158th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 180th largest by planned enrollment of the 256 interventional ones that give a count, is one of 40 that started in 2022, is one of 200 with no phase, and was the 158th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

In recent years, a growing body of research has shown that diabetes plays an important role in the development and recurrence of atrial fibrillation. How to achieve the treatment and prevention of recurrence of atrial fibrillation through appropriate blood glucose control is the current focus of clinical research. Glycosylated hemoglobin (HbA1c) is the product of a non-enzymatic reaction in which hemoglobin in red blood cells is combined with sugars in the serum (mainly glucose). The purpose of this multicenter, randomized controlled study is to compare the effects of different glycosylated hemoglobin control strategies on the effectiveness of Cox-Maze IV procedure for atrial fibrillation during cardiac surgery.

03

Conditions studied

  • Cardiac Surgery

Browse trials for

Keywords

  • Cardiac Surgery
  • Atrial Fibrillation
  • Glycosylated Hemoglobin
  • Cox-Maze IV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Elective cardiac surgery
  • A clear diagnosis of diabetes mellitus, and ≥ 7.5% at the time of initial diagnosis and treatment
  • Preoperative combination of persistent or long-term persistent atrial fibrillation

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery or limited-term surgery
  • Previous cardiac surgery
  • Left atrial diameter > 65 mm
  • Serum creatine > 1.8 mg/dL
  • Previous severe liver disease
  • Pregnant or planning to become pregnant
  • Have a malignant tumor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Preoperative blood glucose control

    Under the guidance of endocrinologists, the patient's hypoglycemic strategy is formulated, follow-up guidance is guided by the patient to take the drug, the HbA1c level is reviewed after 6 weeks, the preoperative HbA1c \< 7.5% is performed surgically, and if it is still above the standard, the hypoglycemic therapy is continued, during which the patient is administered according to the corresponding heart disease type.

    Other: Preoperative blood glucose control

  • No intervention
    Preoperative blood glucose uncontrol

    Patients included in this group ≥ 7.5% preoperative HbA1c and underwent surgery directly

Interventions

  • OtherPreoperative blood glucose control

    Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c\<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.

06

What researchers measure

Primary outcomes

  1. Rate of atrial fibrillation recurrence

    Atrial fibrillation heart rate recorded on a 24-hour Holter electrocardiogram persisted for more than 30 seconds

    Time frame: one year post operative

Secondary outcomes

  1. Rate of atrial fibrillation recurrence

    Atrial fibrillation heart rate recorded on a 24-hour Holter electrocardiogram persisted for more than 30 seconds

    Time frame: 6 months post operative

  2. All-cause Mortality

    All-cause mortality identified during one-year follow-up

    Time frame: one year post operative

07

Study locations

1 of 1 sites recruiting
  • Beijing Anzhen Hospital
    Beijing, China
    Recruiting
    • Zhan Peng · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2024, 24 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 16, 2022
StartActual
May 15, 2022
Primary completionEst.
Jun 7, 2024
CompletionEst.
Aug 31, 2024
Last update
Apr 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05374655
Lead sponsor
Kun Hua
Collaborators
Peking University People's Hospital, Peking University International Hospital, Beijing Huaxin Hospital
Responsible party
Kun Hua (Deputy Chief Surgeon, Beijing Anzhen Hospital) — Sponsor-investigator
First posted
May 16, 2022
Start date
May 15, 2022
Primary completion
Jun 7, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Apr 20, 2023

Study contacts

Kun Hua
Contact
huakun0310@126.com
+8615810111206
Kun Hua
study chair · Beijing Anzhen Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion